Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the This story matters for Science & Discovery readers tracking science. Reported by sciencedaily.com. Read the full original at the source link below.
Originally reported by sciencedaily.com. NewsData.net curates and briefs the science & discovery stories that matter. Our editorial policy →
Get the daily science & discovery signal